GlassScriptPhysician profile
Stacy Quinn
NPI 1427378512
$4,722.41
in general payments reported to CMS, 2019-2025
27 companies · $936 in 2025
The $936 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $999 · 2022: $688 · 2023: $867 · 2024: $1,231 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,034.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,248.21 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,044.68 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $630.65 | 2021-2025 | |
| Novo Nordisk INC | $483.95 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.22 | 2021-2024 | Tradjenta, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $216.08 | 2021-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.63 | 2021-2023 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $119.88 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $99.36 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $61.00 | 2021-2023 | Mounjaro, Trulicity |
| Idorsia Pharmaceuticals US INC | $58.62 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $54.57 | 2022 | |
| Sumitomo Pharma America, INC. | $38.12 | 2023 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.07 | 2023 | |
| Merck Sharp & Dohme LLC | $30.54 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.19 | 2022 | |
| Amgen INC. | $22.67 | 2021-2022 | |
| Astellas Pharma US INC | $18.36 | 2024 | Veozah |
| Abbott Laboratories | $15.84 | 2022 | |
| Genzyme Corporation | $15.39 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.94 | 2025 | Voquezna |
| Tris Pharma INC | $14.87 | 2025 | Dyanavel Xr |
| Mylan Specialty L.P. | $13.95 | 2024 | Yupelri |
| Azurity Pharmaceuticals, INC. | $13.58 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.44 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.24 | 2024 | Strensiq |
| Allergan, INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.